The simultaneous impacts of global trade shifts, U.S. tax reforms, and changing drug pricing policies have prompted life ...

Tom Wells at 4C Associates, explores the future of biologistics, or how the packaging, storage, and logistics for biologics ...

Strong IP keeps collaboration alive, allowing companies to attract capital, strike partnerships, and bring innovations to patients, according to legal experts at Ice Miller.

In a complex global and competitive world, formulating a plan without testing it against likely external reactions is the equivalent of walking into a battlefield without the right weapons or a plan ...

Marc Richards Biotechnology companies often offer a promise of future success, but it can take years to determine whether all the effort (and expense) will translate into returns. Because of the ...

In healthcare, product launches tend to take on a life of their own. The buildup, the planning, and the expectations all revolve around that single moment when a product finally reaches the market.

Since clinical trials have become increasingly complex with more data being collected, this consequently puts more pressure on sponsors to improve efficiencies while still maintaining quality.

“THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes Therapeutics, a genetic medicines company focused on the adeno-associated virus (AAV). It was the fall ...

The False Claims Act (FCA) and the Anti-Kickback Statute (AKS) are two of the Department of Justice’s (DOJ) primary tools when it comes to fighting fraud. Originally enacted during the Civil War to ...

AI is becoming increasingly sophisticated, taking on responsibilities that were once exclusive to human beings. However, there are also disadvantages posed by ethical ...

In the increasingly complex world of artificial intelligence (AI), the concept of "correct outcomes" takes on a profound and sometimes ambiguous meaning. Although efforts are made to create AI that ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...